Key Points
- CFO Troy Wichterman sold 30,000 shares on December 4 at an average price of $25.72 for a total of $771,600, reducing his position by 16.41% to 152,769 shares valued at about $3.93 million.
- Institutional ownership is very high (93.24%), with recent large stakes and increases from firms including T. Rowe Price, Royal Bank of Canada, and Invesco, signaling strong institutional interest.
- For market context, BioLife (NASDAQ:BLFS) has a market cap of roughly $1.23 billion, a 12‑month range of $19.10–$29.62, and a consensus analyst rating of "Moderate Buy" with a target price of $31.20.
BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CFO Troy Wichterman sold 30,000 shares of the company's stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $25.72, for a total value of $771,600.00. Following the completion of the transaction, the chief financial officer owned 152,769 shares of the company's stock, valued at approximately $3,929,218.68. This represents a 16.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Troy Wichterman also recently made the following trade(s):
- On Tuesday, November 25th, Troy Wichterman sold 584 shares of BioLife Solutions stock. The shares were sold at an average price of $26.74, for a total transaction of $15,616.16.
- On Thursday, October 9th, Troy Wichterman sold 833 shares of BioLife Solutions stock. The shares were sold at an average price of $27.36, for a total transaction of $22,790.88.
- On Thursday, September 11th, Troy Wichterman sold 1,032 shares of BioLife Solutions stock. The shares were sold at an average price of $26.83, for a total transaction of $27,688.56.
BioLife Solutions Price Performance
BioLife Solutions stock opened at $25.46 on Friday. BioLife Solutions, Inc. has a 12-month low of $19.10 and a 12-month high of $29.62. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of -363.66 and a beta of 1.93. The firm's fifty day moving average price is $26.55 and its 200 day moving average price is $24.36.
Institutional Trading of BioLife Solutions
Several hedge funds and other institutional investors have recently bought and sold shares of BLFS. T. Rowe Price Investment Management Inc. acquired a new stake in BioLife Solutions during the first quarter valued at approximately $30,789,000. Royal Bank of Canada increased its holdings in shares of BioLife Solutions by 762.8% in the 1st quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider's stock valued at $15,948,000 after acquiring an additional 617,320 shares during the last quarter. Invesco Ltd. increased its holdings in shares of BioLife Solutions by 9.6% in the 1st quarter. Invesco Ltd. now owns 3,551,054 shares of the medical equipment provider's stock valued at $81,106,000 after acquiring an additional 311,585 shares during the last quarter. Qube Research & Technologies Ltd raised its position in shares of BioLife Solutions by 2,399.5% during the 2nd quarter. Qube Research & Technologies Ltd now owns 248,474 shares of the medical equipment provider's stock valued at $5,352,000 after acquiring an additional 238,533 shares in the last quarter. Finally, Summit Creek Advisors LLC acquired a new stake in shares of BioLife Solutions during the 3rd quarter valued at approximately $4,905,000. 93.24% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of brokerages have recently issued reports on BLFS. Wall Street Zen lowered BioLife Solutions from a "buy" rating to a "hold" rating in a research report on Sunday, November 30th. Weiss Ratings restated a "sell (d-)" rating on shares of BioLife Solutions in a research note on Wednesday, October 8th. HC Wainwright restated a "buy" rating and set a $32.00 price objective on shares of BioLife Solutions in a report on Monday, November 24th. Finally, Zacks Research upgraded BioLife Solutions from a "hold" rating to a "strong-buy" rating in a research note on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, BioLife Solutions currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.20.
Read Our Latest Research Report on BioLife Solutions
About BioLife Solutions
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
